Boundless Bio IncBOLD
Price$2.59

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$64MTTM through 30 Jun 2026
Free Cash Flow -$56.7MTTM through 30 Jun 2026

Margins

Current

Returns

-64.8%ROE
-39.7%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio9.48x
Net Debt-$44.6Mnet cash position
Cash & Equivalents$20.2M

Quality Metrics

Altman Z-Score-2.55
Piotroski F-Score1 / 9
Earnings-Beat Rate0.0%

Multi-Year Trend

Diluted EPS-$2.85TTM
'23'24'25
FY2025: $-2.60

Dividend

No dividend

Capital Allocation

R&D Spend$44.2M

Segment Performance

No segment data available.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.